glycopyrrolate (PT001) / AstraZeneca - LARVOL DELTA

Transcriptomics-proteomics analysis reveals StCOMT1 regulates drought, alkali and combined stresses in potato. (PubMed, Plant Cell Rep) - "In this study, we investigated the changes in physiologic characteristics, such as growth, antioxidant defense, osmotic regulation and lignin accumulation, in overexpressing StCOMT1 (PT0001512/M0ZIL7) transgenic potato after stress. It proved that the gene has the function of adapting to drought and alkali stress, and provided a theoretical basis for further research on the resistance mechanism of the gene in drought and alkali tolerance in potato."

Journal • COMT

Molecular identification of a thioredoxin peroxidase in Babesia gibsoni with potential against oxidative stress. (PubMed, Parasitol Res) - "There are two conserved "VCP" domains at the N- and C-termini, respectively, indicating that this gene was a 2-Cys peroxiredoxin belonging to the PTZ00137 superfamily...Additionally, its antioxidant activity was analyzed by mixed-function oxidation assay, and BgTPx-2 could protect the pBluescript SK ( +) plasmid from oxidative damage, suggesting an antioxidant function of BgTPx-2. Moreover, the immunogenicity of BgTPx-2 was tested by Western blotting and ELISA using the serum of beagle dogs infected with B. gibsoni, and the positive serum exhibited a detectable and significant antibody response against BgTPx-2 on day 4 and day 9 post-infection, respectively."

Journal • Infectious Disease

Mesoporous Silica Nano-Modified Ginsenoside Rh2 Promote Tumor Immunosuppression and Inhibit Lung Cancer Development through the PD-1/PD-L1 Pathway. (PubMed, Ann Clin Lab Sci) - "We clarified the mechanism for G-Rh2-MSN in lung cancer A549 cells, showing that it can significantly down-regulate PD-1/PD-L1 signaling, thereby promoting tumor immunity. G-Rh2-MSN modified material inhibits immune escape and reduces behaviors of lung cancer A549 cells by affecting PD-1 and PD-L1 expression, which has potential clinical application prospects."

IO biomarker • Journal • Lung Cancer • Oncology • Solid Tumor

The Reconstruction of Pt(001) Surface and the Shell-Like Reconstruction of the Vicinal Pt(001) Surfaces Revealed by Neural Network Potential. (PubMed, Small) - "In agreement with experimental observations, the optimized supercell size of the reconstructed Pt(001) surface contains (5 × 20) unit cells. Surprisingly, the reconstruction of the vicinal Pt(001) surfaces leads to a smooth shell-like surface layer covering the whole surface and diminishing sharp step edges."

Journal

AAR-PT-001. AAR Poster Spotlight (ASM Microbe 2024) - No abstract available

EEB-PT-001. EEB Poster Spotlight (ASM Microbe 2024) - No abstract available

CIV-PT-001. CIV Awardee Spotlight: “Innovative Initiatives in Diagnostics and Therapeutics” (ASM Microbe 2024) - No abstract available

CPHM-PT-001. CPHM Awardee Spotlight (ASM Microbe 2024) - No abstract available

MBP-PT-001. MBP Poster Spotlight - Cellular Decision Making (ASM Microbe 2024) - No abstract available

AES-PT-001. AES Sunday Spotlight: Where it is and what it's doing (ASM Microbe 2024) - No abstract available

HMB-PT-001. Spotlight: Recent Advances in Microbiota of the Digestive Tract (ASM Microbe 2024) - No abstract available

PT001. AES Poster Spotlights: Biofilms and Motility (ASM Microbe 2023) - No abstract available

Early Outcome of a Phase I/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) (TCT-ASTCT-CIBMTR 2020) - P1/2; "All 3 are now off isolation and managed as outpatients, although 2 developed autoimmune hemolytic anemia (AIHA) that resolved in PT001 by 18m of age and did not require therapy in PT002. Infusion of AProArt-transduced autologous CD34+ cells into ART-SCID infants pretreated with very low exposure busulfan has resulted in multilineage engraftment of transduced cells with reconstitution of T cell immunity and evidence for B cell immune development. AIHA, the only complication, has resolved upon development of T cell immunity."

Clinical • P1/2 data • CD34 • CD8

Inhibition of protein arginine methyltransferase 1 alleviates liver fibrosis by attenuating the activation of hepatic stellate cells in mice. (PubMed, FASEB J) - "Applying a selective inhibitor of PRMT1, PT1001B, significantly suppressed PRMT1 activity and mitigated liver fibrosis in mice...Inhibition of PRMT1 mitigates hepatic fibrosis by attenuating HSC activation in mice. Therefore, targeting PRMT1 could be a feasible therapeutic strategy for liver fibrosis."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • PRMT1 • TGFB1

PT001 - Immune-Inflammatory Dermatological Diseases: Mechanisms and Manifestations (AAD 2022) - "Exhibiting Company: Pfizer Inc. Theater 1: Booth 4471"

Dermatology

BRIDGING RADIOTHERAPY TO CAR-T CELL THERAPY IN REFRACTORY NON-HODGKIN B LYMPHOMA: SINGLE-CENTER EXPERIENCE (AIOM 2021) - "Four patients received tisagenlecleucel (tisa-cel), and one axicabtagene-ciloleucel (axi-cel); one patient died before reinfusion of CAR-T. The dose of RT was 30 Gy in 15 fractions, the site was mediastinum for pt 001, abdominal adenopathy for pt 002, 003 and 005, inguinal adenopathy for pt 004, laterocervical adenopathy for pt 006)... We showed in this report that RT is feasible and effective as bridging therapy for patients with localized disease before CAR-T therapy."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases

BRIDGING RADIOTHERAPY TO CAR-T CELL THERAPY IN REFRACTORY NON-HODGKIN B LYMPHOMA: SINGLE-CENTER EXPERIENCE (SIE 2021) - "Four patients received tisagenlecleucel (tisa-cel), and one axicabtagene-ciloleucel (axi-cel); one patient died before reinfusion of CAR-T. The dose of RT was 30 Gy in 15 fractions, the site was mediastinum for pt 001, abdominal adenopathy for pt 002, 003 and 005, inguinal adenopathy for pt 004, laterocervical adenopathy for pt 007)...Only one patient receiving axi-cel needed admission at ICU for grade 4 ICANS, with complete resolution after treatment with high dose steroids. We showed in this report that RT is feasible and effective as bridging therapy for patients with localized disease before CAR-T therapy"

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases

"PT001 for PAH Earns Orphan Drug Status https://t.co/kKmOveAdCp #PAH #PulmonaryArterialHypertension #RareDisease @PHAssociation" (@PatientWorthy)

Orphan drug • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Respiratory Diseases

"A $1.85 Billion investment. @PandionTx @Merck #PT101 #Tregs #PT001 #PD1 #MAdCAM #TALON" (@thesugarscience)

PD-1

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. (PubMed, World J Gastroenterol) - "PT1001B enhances antitumor immunity and combining it with anti-PD-L1 checkpoint inhibitors provides a potential strategy to overcome anti-PD-L1 resistance in PDAC."

IO Biomarker • Journal • Gastrointestinal Cancer • Immune Modulation • Inflammation • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Transplantation • CD8 • PD-1

Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction: Is It actually a Matter of Chronotropic Reluctance? (AHA 2016) - "To limit neural influence on HR during ISO, dexmedetomidine (α-2 agonist) and glycopyrrolate (muscarinic antagonist) were used to “denervate” the sinus node. Despite lower peak exercise HR, increases in HR due to central command and to β-receptor stimulation were intact in HFpEF subjects. Our findings suggest that apparent chronotropic incompetence might reflect premature cessation of exercise rather than deficient central command or ß-adrenoceptor responsiveness."

Clinical • Biosimilar • Cardiovascular • Heart Failure

GOLDEN-3-Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - P3; N=645; Active, not recruiting; Sponsor: Sunovion Respiratory Development Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation

Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys. (PubMed, FASEB J) - "Moreover, ADMA reduced the NO concentration in PT1001B-treated HK2 cells. Finally, we conclude that ADMA has an antifibrotic effect in obstructed kidneys, and future application of type I PRMT inhibitor should be done cautiously for patients with CKD.-Wu, M., Lin, P., Li, L., Chen, D., Yang, X., Xu, L., Zhou, B., Wang, C., Zhang, Y., Luo, C., Ye, C. Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD (clinicaltrials.gov) - P4; N=50; Not yet recruiting; Sponsor: Los Angeles Biomedical Research Institute

New P4 trial • Biosimilar • Chronic Obstructive Pulmonary Disease

Decision Support for Intraoperative Low Blood Pressure (clinicaltrials.gov) - P=N/A; N=16000; Not yet recruiting; Sponsor: Vanderbilt University; Initiation date: May 2016 ➔ Dec 2016; Trial primary completion date: Oct 2017 ➔ May 2018

Trial initiation date • Trial primary completion date • Acute Kidney Injury • Biosimilar